9. SUBSEQUENT EVENTS

In April 2017, we provided a Letter of Termination to UBC, notifying them that we have discontinued development of OGX-225 resulting in termination of the license agreement related to this product candidate. We believe that all financial obligations, other than continuing mutual indemnification obligations and our requirement to pay for out-of-pocket patent expenses incurred up to the date of termination and for abandoning the OGX-225 patents and patent applications, under all OGX-225-related agreements UBC, are no longer owed and no further payments are due.

On May 3, 2017, we and Achieve entered into Amendment No. 1 to Agreement and Plan of Merger and Reorganization, pursuant to which the parties agreed that the reverse stock split of our common stock to occur prior to the closing of the merger shall not exceed a combination of 20-for-1.